Asset profile
Ezetimibe · Zetia
Small molecule
Evidence outlook
Approved: ZETIA ® is indicated: In combination with a statin, or alone when additional low-density... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 18 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ezetimibe (Zetia): this drug | Phase 3 | Small molecule | NPC1L1, Dietary Cholesterol Absorption Inhibitor | ||
| Hyzetimibe | Phase 3 | Small molecule | NPC1L1 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | ||
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | ||
| Nexlizet | Approved | — | — | ||
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(19 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (8)
January 2027 (2)
February 2027 (1)
What to watch
July 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (6)
February 2028 (1)
What to watch
March 2028 (2)
June 2028 (2)
What to watch
What to watch
September 2028 (1)
What to watch
2029 (3)
July 2029 (1)
What to watch
September 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
2032 (1)
June 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.